Latest News
Jasper Therapeutics, Inc.
- Jasper Therapeutics completes enrolment in Phase 2 kidney-cohort study of KP104 in IgA nephropathy
- Jasper Therapeutics Completes IgA Nephropathy Enrollment for KP104 Phase 2 Study
- Jasper Therapeutics completes IgAN cohort enrollment; interim data due by year-end 2026
- Kidney study cohort enrollment ends at Jasper Therapeutics (JSPR), with interim data expected by year-end 2026.
- Jasper Therapeutics Announces Completion of Enrollment in
- Jasper Therapeutics Registers 284 Million PIPE Shares for Resale via Form S-3 Filing
- Jasper Therapeutics launches offer to buy back outstanding warrants
- Jasper Therapeutics launches tender offer for warrants By Investing.com
- Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
- Jasper Therapeutics announces CFO resignation and interim appointments By Investing.com
- Herb Cross to Resign as Jasper Therapeutics CFO; Jeet Mahal, Rick Ruiz and Matthew Ros Appointed to Interim Roles
- Jasper Therapeutics stock gains 1.39 percent on Nasdaq
Headlines from the last 30 days, linking to the original publishers. See all market news →